Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll

January 11, 2010

Limiting Fees from Industry to Academic Consultants

Massachusetts General Hospital and Brigham and Women's Hospital have placed limits on the outside, institutional pay a number of their senior officials can receive from biotechnology and pharmaceutical companies on whose boards these officials may sit. The decisions were largely dictated by complaints from within and outside the bioindustry and academia over conflict-of-interest issues. Do you think such pay limits represent a good policy move?

Will capping academic consultants' pay from companies impact academic/industry collaborations?

  {{ choice.Percent }}%